Monday, April 16, 2018 8:48:20 AM
For immediate release. Vancouver, British Columbia, April 16, 2018: Cannabix Technologies Inc.(CSE: BLO, OTC PINK: BLOZF) (the “Company”) developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to report it has filed a Patent Cooperation Treaty (“PCT”) application titled, “Device and Method for Detection of Cannabis and Other Controlled Substances Using FAIMS” (PCT/CA2017/000042). This PCT covers intellectual property related to earlier versions of the Cannabix Marijuana Breathalyzer. Under its relationship with the University of Florida (“the University”), the Company has entered into a second license agreement with the University for PCT application CA2017/000042. The agreement provides Cannabix exclusive worldwide rights in the area of breath analysis of controlled substances. Cannabix is developing an innovative FAIMS (field asymmetric waveform ion mobility spectrometry) based instrument for the detection of ?9-tetrahydrocannabinol in human breath.
In recent months the Company has been characterizing its Beta 3.0 Cannabix Marijuana Breathalyzer prototype performance measures both independently and coupled to a mass spectrometer (MS), in preparation for expanded field testing. This work has led to the design and development of several improvements to the device which are now being incorporated. The characterizing work has focused on better separation of several analytes in human breath that are similar in molecular mass and geometry to THC. Testing has included further temperature characterization and flow control. A unique gating system has been developed that allows switching between the standalone FAIMS detector and a conventional MS enabling rapid alternation between both mechanisms during a single breath, proving enhanced analysis capability.
THC and related metabolite characterization
Marijuana contains several cannabinoids in addition to ?9-tetrahydrocannabinol (“THC”). Many of these have shorter half-lives and are metabolized in the body relatively quickly. THC can be detectable in blood for weeks, whereas metabolites such as 11-hydroxy-delta-9-tetrahydrocannabinol and 11-nor-9-carboxy-tetrahydrocannabinol are only detectable for a few hours after consumption of cannabis. The Cannabix FAIMS device has demonstrated the detection of THC and related metabolites in MS-coupled testing. The detection of THC and its metabolites in human breath provides for real-time pharmacokinetic analysis. Such analysis provides a method for the identification of “recency of use” and also provides analysis of frequent users of marijuana who tend to retain THC in their body for longer periods of time, relative to infrequent marijuana users who tend to clear THC from their body more quickly. This data and analysis will be important for an eventual court approved device, furthermore, 11-nor-9- carboxy-tetrahydrocannabinol is the primary metabolite from the liver, which is prevalent from the consumption of edibles. Cannabix scientists are working quickly to complete this characterization stage.
The Company also reports that it has renewed its ongoing research agreement for 2018 with the Dr. Yost lab at the University of Florida.
Recent BLOZF News
- Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • InvestorsHub NewsWire • 04/30/2024 12:53:40 PM
- Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • InvestorsHub NewsWire • 04/25/2024 12:52:01 PM
- Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • InvestorsHub NewsWire • 04/22/2024 12:49:29 PM
- Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • InvestorsHub NewsWire • 04/16/2024 12:52:49 PM
- Cannabix Quantifies Marijuana Breath Samples from Maryland Green Lab - Results Analyzed at North Louisiana Criminalistics Laboratory • InvestorsHub NewsWire • 01/18/2024 02:56:11 PM
- Shares Up on Patent Filing for Marijuana Breathalyzer • AllPennyStocks.com • 01/03/2024 07:00:00 PM
- Cannabix Technologies Files Patent for Proprietary Laboratory Drug Analysis Device • InvestorsHub NewsWire • 01/03/2024 02:30:21 PM
- Cannabix Technologies to Participate in Green Lab Held by Montgomery County Police Department (Maryland) • InvestorsHub NewsWire • 12/22/2023 01:46:36 PM
- Cannabix Completes Initial Electronics Testing on Contactless Alcohol Breathalyzer, Commences International Certification Plans • InvestorsHub NewsWire • 11/07/2023 02:09:46 PM
- Cannabix's MSBS Marijuana Breathalyzer Technology Advances Quantification of THC in Breath • InvestorsHub NewsWire • 10/03/2023 12:50:42 PM
- Cannabix Technologies Files Breath Sample Capture Patent and Detects Delta- 8 THC in Early Testing • InvestorsHub NewsWire • 08/04/2023 12:52:02 PM
- Cannabix's MSBS Marijuana Breathalyzer Technology Detects THC in Breath after Edibles Consumption • InvestorsHub NewsWire • 06/14/2023 12:55:03 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM